Cutting Through The Confusion On US Biosimilar Interchangeability
Experts Offer Clarity Amid Misunderstandings Over US FDA Designation
Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk to Generics Bulletin about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings around biosimilars.
